# An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)

> **NCT03699449** · PHASE2 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 104 (estimated)

## Conditions studied

- Platinum-resistant Recurrent Ovarian Cancer

## Interventions

- **DRUG:** olaparib+cediranib combination therapy
- **DRUG:** durvalumab + olaparib combination therapy
- **DRUG:** durvalumab + chemotherapy treatment
- **DRUG:** durvalumab + tremelimumab + chemotherapy treatment
- **DRUG:** durvalumab + tremelimumab + paclitaxel treatment
- **DRUG:** durvalumab +chemotherapy treatment

## Key facts

- **NCT ID:** NCT03699449
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-26
- **Primary completion:** 2022-09
- **Final completion:** 2022-09
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2021-04-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03699449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03699449, "An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03699449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*